BerGenBio ASA (OSL:BGBIO)

Norway flag Norway · Delayed Price · Currency is NOK
1.764
-0.054 (-2.97%)
Apr 24, 2025, 4:25 PM CET
-88.76%
Market Cap 68.95M
Revenue (ttm) 848.00K
Net Income (ttm) -139.28M
Shares Out 39.09M
EPS (ttm) -3.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 68,900
Average Volume 577,462
Open 1.790
Previous Close 1.818
Day's Range 1.720 - 1.820
52-Week Range 1.450 - 16.780
Beta 1.77
RSI 39.34
Earnings Date Apr 29, 2025

About BerGenBio ASA

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. The company’s lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC). It develops Bemcentinib, which is in preclinical trial to treat acute... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 15
Stock Exchange Oslo Børs
Ticker Symbol BGBIO
Full Company Profile

Financial Performance

In 2024, BerGenBio ASA's revenue was 848,000, an increase of 139.55% compared to the previous year's 354,000. Losses were -139.28 million, -26.85% less than in 2023.

Financial Statements

News

BerGenBio ASA (STU:7BG0) Q4 2024 Earnings Call Highlights: Strategic Review and Financial ...

BerGenBio ASA (STU:7BG0) Q4 2024 Earnings Call Highlights: Strategic Review and Financial Management in Focus

2 months ago - GuruFocus